Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Decreases By 54.4%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a significant decline in short interest in August. As of August 31st, there was short interest totaling 5,707 shares, a decline of 54.4% from the August 15th total of 12,512 shares. Based on an average trading volume of 16,436 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.3% of the company’s stock are sold short.

Hedge Funds Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. HRT Financial LP purchased a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned approximately 0.54% of Alaunos Therapeutics as of its most recent filing with the Securities and Exchange Commission. 27.72% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Alaunos Therapeutics Price Performance

Shares of NASDAQ:TCRT opened at $1.51 on Monday. Alaunos Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $4.59. The company has a market cap of $3.84 million, a PE ratio of -0.79 and a beta of -0.97. The company’s 50-day moving average price is $1.88 and its 200 day moving average price is $2.43.

Alaunos Therapeutics (NASDAQ:TCRT) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.41) EPS for the quarter.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.